• Home
  • Study Details
Coming Soon

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent GvHD. We are doing this study to see if a lower dose of cyclophosphamide after transplant is safer, but just as effective. Cyclophosphamide can prevent GvHD, but it can also make you sick and more likely to get an infection. This study will look at how well a lower dose of cyclophosphamide works to reduce these side effects, while also preventing GvHD. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for transplant.

Age & Gender

  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Katarzyna Jamieson
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia, Lymphoma)
Transplant

IRB Number

23-2527

ClinicalTrials.gov

NCT06001385

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research